About US
Contact us
-
Teva says no thank you to generic LipitorGenerics makers are preparing to flood the market with copycat Lipitor, now that Ranbaxy Laboratories' exclusivity period is expiring. But Teva Pharmaceutical Industries ($TEVA) won't be joining th2012/5/30
-
EMA supports Pradaxa but seeks sharper warnings for bleedingEuropean regulators say the upside of blockbuster drug Pradaxa still outweighs its the risks of fatal bleeding, but they want some more labeling caveats for the blockbuster drug. The European Medicin2012/5/29
-
House could vote on FDA bill next weekThe Senate Thursday voted 96-1 vote in favor of re-authorization of PDUFA. It now goes to the House, whose own version to extend the user-fee act for another 5 years is similar to the Senate's bill, T2012/5/29
-
SFDA Commissioner Yin Li attends the opening ceremony of the 4th DIA China Annual MeetingOn May 21, 2012, Yin Li, Commissioner of the State Food and Drug Administration (SFDA), attended the opening ceremony of the 4th DIA (Drug Information Association) China Annual Meeting in Shanghai and2012/5/28
-
FDA panel draws blood in Xarelto's bid for new useLesson from FDA's panel meeting on Xarelto: Beware of "missingness." After a spirited debate over some missing study data, the advisory committee refused to back a big new use for the blood thinner. B2012/5/25
-
Sanofi eyes Chinese cancer market with early drug trialSanofi($SNY) CEO Chris Viehbacher is betting that an experimental liver cancer drug could make big inroads in China. The company is going ahead with the first human trials of the drug next year.2012/5/25
-
Study: Docs barring pharma reps has unexpected side effectsPharma reps, take heart. A new study finds that barring you from doctors' offices has some deleterious effects. It cut back on adoption of a brand-new, first-in-class diabetes drug--Merck's ($MRK)2012/5/24
-
Merck CEO assures shareholders there is life after death of Singulair patentWith its $5.5 billion seller Singulair going off patent in two months, things will be a little dicey for the next couple of years at Merck ($MRK). But CEO Kenneth Frazier assures shareholders that2012/5/24
-
Bayer's Nexavar falters in another lung cancer trialOnce again, Bayer sent Nexavar out to conquer new lung cancer territory. And once again, the disease defended itself too well. The company and its Nexavar partner, Onyx Pharmaceuticals ($ONXX), said t2012/5/23
-
Fired Pfizer rep sues, claiming pregnancy-related discriminationA Pfizer ($PFE) sales rep has sued the company, saying she was fired because of her pregnancy, Pharmalot reports. Marie Hand, who repped for King Pharmaceuticals when Pfizer bought the company, says s2012/5/23